Asthma remains a significant health burden in the U.S., with more than 60% of adults continuing to experience frequent symptoms despite the ...
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV ...
Johnson & Johnson today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human ...
About the MASCOT trial MASCOT (NCT06706622) is a Phase 3 interventional, randomized, double-blind, parallel-group, placebo-controlled, optional open-label extension trial that will be conducted in ...
FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line ...
Dr. Mark Harper recalls his first cold-water swim in the south of England 20 years ago. It was August, but the initial jolt ...
More than 75% of the planet's health and life support systems are in danger. The climate crisis is not a distant threat; it's happening right now and affecting what matters most to us. Hurricanes ...
We all know that asthma impacts breathing. What may be less known is that the disease, which restricts our airways due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback